Investigations of the biochemical actions of lithium have identified many individual reactions that are affected, especially within cellular signaling systems, but the actions of lithium at different sites often appear opposing and difficult to integrate into a general mechanism of action. A bimodal mechanism of action of lithium is proposed which is in accord with many of the apparently contradictory results that have been published. This model describes the critical effect of lithium as that of a stabilizer of the magnitude of fluctuations of signaling processes. This is achieved by lithium balancing positive and negative regulators of signaling processes which results in lithium raising basal activities and diminishing maximal activities, thereby stabilizing signaling activities within an optimal range and preventing fluctuations either above or below this optimum. This model is shown to be applicable to many published results concerning the activation of AP-1 DNA binding and cyclic AMP production. Diverse sites of action of lithium are proposed to ultimately converge on the regulation of gene expression to contribute to mood stabilization.
Introduction
How does lithium work? For almost 50 years this question has perplexed investigators interested in its mechanism of action. During this time, many biochemical actions of lithium were identified which provided the basis for numerous hypotheses, generally targeted to isolated sites of action, that were proposed to explain lithium's mechanism of action. Recently much of the research concerning lithium has focused on how it changes the activities of cellular signal transduction systems, especially the phosphoinositide and cyclic AMP second messenger systems. [1] [2] [3] Within the last couple of years, this has progressed to encompass explorations of lithium's effects on the regulation of transcription factor DNA binding activity, a process that controls the expression of specific genes. This was proposed as a logical target for two reasons: 4 gene expression is highly likely to be influenced by a drug, like lithium, that requires chronic administration to achieve a therapeutic effect, and transcription factors are pivotal in connecting transient signaling second messengers (which appear to be affected by lithium) to more stable changes that can result from altered gene expression and the associated synthesis of proteins. These studies suggest that lithium's actions on signaling systems provide critical contributions to its therapeutic effect (reviewed in Refs 2,3).
In spite of this progress identifying individual reactions affected by lithium, it has been difficult to compose a model that integrates multiple biochemical effects of lithium. This situation exists in part because findings from many of the studies of lithium's effects on signaling systems often appear opposing and contradictory, and therefore confusing (as described below). However, the apparently contradictory effects of lithium are consistent with a model in which lithium, as well as other anti-bipolar therapeutics, stabilizes fluctuations in cellular responses, which in turn, may be the foundation for lithium's mood stabilizing action. This model's premise is that lithium facilitates the balancing of positive and negative regulators of signaling processes, thereby stabilizing activities within an optimal range and preventing fluctuations either above or below the optimum. This is opposed to previously prevalent hypotheses of lithium's actions which focused on the unidirectional regulation of individual reactions.
The model
The bimodal model of lithium's mechanism of action is depicted in Figure 1 . This scheme shows that an excessive response to a stimulus (S) can be controlled by lithium in a bimodal manner as a result of lithium both raising the lowest level of baseline activity and attenuating the maximum peak activity. Thus, by acting at different sites with apparently opposing actions, lithium reduces the low and high extremes, resulting in a stabilization of the fluctuations in activity without completely blocking a response. Biochemical evidence for this bimodal model of the mechanism of action of lithium is discussed below.
Application of the model to AP-1
One example of how this model reconciles opposite effects of lithium, which at first appeared contradictory, is provided by recent studies of a particularly intriguing transcription factor called AP-1 (activator protein-1). 5 Initially, lithium was reported to inhibit stimulus-induced increases in AP-1 DNA binding activity, both in rat brain after chronic lithium treatment 4 and in cultured cells. 6, 7 Another anti-bipolar agent, valproic acid, has the same inhibitory effect (Pacheco and Jope, unpublished observations). However, lithium, as well as valproic acid, were recently reported to elevate the basal, unstimulated AP-1 DNA binding activity, leading to the conclusion from the latter studies that anti-bipolar therapeutics activate AP-1.
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Thus, these findings appeared to be directly contradictory, and it was difficult to discern whether lithium was increasing or decreasing the activity of this important transcription factor. However, as indicated in Figure 2 , both actions of lithium can play complementary roles in contributing to stabilization of the magnitude in fluctuations in the activity of AP-1. Integrating these results demonstrates that lithium both raises the lowest, basal activity and diminishes the stimulated highest, peak activity. Thus seemingly contradictory findings resulted from experimental design, whether investigators focused on the action of lithium on basal or stimulated AP-1 DNA binding activity, and each result actually contributes an individual piece of the puzzle in support of the bimodal model of lithium's action which emphasizes an overall stabilization of fluctuations in signals rather than focusing on isolated actions of the drug.
Mechanisms affecting AP-1 activity
These findings concerning the regulation of AP-1 DNA binding provide one example of how this model may diffuse some of the controversies in lithium research by demonstrating that multiple actions of lithium may be complementary. The specific mechanisms that are understood about lithium's actions on the activation of AP-1 DNA binding provide a useful example of how diverse sites of action can converge to minimize the magnitude of signal fluctuations at the level of regulation of gene expression.
AP-1 DNA binding activity is increased, among several mechanisms, as a result of receptor-coupled, Gprotein-mediated phosphoinositide hydrolysis. This signaling system produces second messengers within cells that have a variety of actions, such as stimulation of protein kinase C, leading to activation of AP-1. Substantial evidence indicates that lithium impairs phosphoinositide signaling. Evidence for a mechanism of this inhibition includes reports that lithium impairs the function of G-proteins, 11, 12 causes depletion of inositol, 2,13-15 reduces protein kinase C activity, [16] [17] [18] [19] or has other sites of action which attenuate signaling through this system. While the specific target of the inhibitory effect of lithium remains unresolved, each of these sites of action leads to the common conclusion that lithium attenuates the magnitude of the signal emanating from the phosphoinositide signal transduction system, consequently attenuating the stimulusinduced increase in AP-1 DNA binding activity.
However, there has been much interest in the recent discovery 20, 21 of a completely different, and apparently opposing, action of lithium, the inhibition of glycogen synthase kinase-3␤ (GSK-3␤), an enzyme that has multiple effects besides its first described action of phosphorylating glycogen synthase. GSK-3␤ is constitutively active, thus it normally maintains a high level of activity. The interesting connection to AP-1 is that the normal high activity of GSK-3␤ maintains basal AP-1 at a low level (by regulating the phosphorylation of cjun, a protein component of the AP-1 complex). 22 Therefore, inhibition of GSK-3␤ by lithium blocks this negative control of AP-1, resulting in an elevation in the basal state of AP-1 DNA binding activity.
Thus, through two entirely separate actions, inhibition of phosphoinositide signaling and inhibition of GSK-3␤, lithium is able to simultaneously decrease the highest, stimulus-induced AP-1 DNA binding activity and raise the lowest, basal AP-1 DNA binding activity, respectively. This bimodal action of lithium ensures that the activity of AP-1 is not too low while at the same time protecting the cell from an overly extreme increase in AP-1 activity, providing a stabilizing influence on signal fluctuations. Since the function of AP-1 is that of a transcription factor controlling gene expression, the same stabilizing effect can be predicted to be induced by lithium on these regulated genes, providing a long-lasting stabilization of the AP-1-sensitive genes and proteins expressed in affected cells. These findings highlight how diverse sites affected by lithium can converge to stabilize gene expression regulation. Although much remains to be learned about the actions of other anti-bipolar therapeutics, according to this model multiple different sites of action can integrate to effectively modify the peaks and troughs of activity to contribute to stabilization.
Application of the model to cyclic AMP
Although this bimodal model of lithium's therapeutic effect matches well with results of studies of AP-1 DNA binding activity, and heuristically with mood stabilization, the question must be addressed of whether studies of other signaling systems also are in accord with the bimodal model of lithium's action. In fact, there is substantial evidence for the same bimodal effect of lithium on the production of cyclic AMP, one of the most prevalent second messengers in the brain (Figure 3) .
Receptor-mediated production of cyclic AMP is controlled by a stimulatory G-protein, Gs, and a counterbalancing inhibitory G-protein, Gi. 23 Under basal conditions, cyclic AMP production is tonically inhibited by the prevailing Gi influence. Several studies have shown that lithium increases basal cyclic AMP levels (reviewed in Refs 1, 24, 25) . This is likely at least in part because lithium reduces the activity of Gi, apparently by shifting its equilibrium between a free active conformation and an inactive heterotrimeric conformation towards the inactive form. 26, 27 Therefore, inhibitory effects of lithium on Gi can elevate the basal level of cyclic AMP. On the other hand, there are many reports that lithium attenuates stimulus-induced increases in cyclic AMP production. 1, 24, 25 This inhibition of the responses to stimuli, such as norepinephrine, may be caused by an inhibitory effect of lithium on Gs, but the specific mechanism mediating this action is not entirely clear.
These contradictory actions of lithium, elevation of basal cyclic AMP levels and decreased stimulusinduced increases in cyclic AMP, made it difficult to know which may be of greater consequence for neuronal function. However, these apparently opposing effects of lithium can be conceptualized as being complementary in attenuating maximal fluctuations of this major signaling process, with lithium elevating minimal levels and diminishing peak levels. Additionally, although not yet studied by many laboratories, the effects of other anti-bipolar therapeutics, such as carbamazepine, overlap at least partially with those of lithium in modulating cyclic AMP levels. [28] [29] [30] Since cyclic AMP can modulate transcription factors 31 which regulate the expression of many genes, stabilization by lithium of fluctuations in cyclic AMP should contribute to stabilization of the regulated genes in affected cells. Thus the bimodal model provides a framework for apparently opposing actions of lithium to be integrated into a unifying hypothesis based on minimization of the magnitude of fluctuations in signaling system activities and the consequential regulation of gene expression.
Current limitations
This model of the actions of lithium and other antibipolar therapeutics proposes that these agents balance positive and negative regulators of signaling processes to stabilize activities within an optimal range. Among the limitations of this model is that there are assuredly differences among cell types, brain regions, and neural networks that likely influence the predominance of the effects of anti-bipolar therapeutics on basal or peak signaling activities depending upon which factors exert the greatest control in each cell system. Additionally, not all investigations have revealed evidence for bimodal effects of each of the anti-bipolar agents under study, and the responses to various stimuli may be modulated differently by lithium and other mood stabilizers. Thus, it seems unlikely that in all cell systems lithium and other anti-bipolar therapeutics will induce equivalent elevations in basal AP-1 and cyclic AMP and inhibitions of increases in response to all stimuli. Clearly further research is needed to compare the effects of other anti-bipolar therapeutics, such as carbamazepine and valproic acid, with those of lithium on signaling activities.
Another limitation of this model is that at this point only two signaling systems have been studied in sufficient detail to be assessed by this model. There is little doubt that additional signaling intermediates, such as other transcription factors, are likely to be influenced by anti-bipolar therapeutics. Nonetheless, these two, AP-1 and cyclic AMP, may typify how positive and negative regulators of signaling can be balanced by diverse actions of lithium and experience from these two systems demonstrates the great influence of experimental design on outcomes, and conse-quentially interpretations of mechanisms of action. The bimodal model provides a framework for these variables to be integrated into a unifying conceptualization of the actions of therapeutic interventions. Further balance and integration must exist at the level of gene expression, as well as the consequential synaptic remodeling accompanying long-term treatments. Thus, balance may be achieved at the level of signaling molecules, as exemplified by cyclic AMP, on molecules regulating transcription, as exemplified by AP-1, or likely on further downstream processes, such as on the expression of proteins with counter-balancing activities.
Summary and future prospects
If this model of the actions of mood stabilizing agents can be extrapolated to mood, it is apparent that mood is likely modulated by positive and negative regulators of signaling processes. Such a balance is a common theme in signaling systems, such as the well known balance between protein phosphorylation and dephosphorylation, and has also been proposed to be the underpinning of such critical functions as memory formation. 32 As pointed out by Abel et al 32 in reviewing memory formation, signaling systems that function beyond optimum ranges, whether too high or too low, cause deleterious consequences. Thus it is evident that it is critical to maintain signaling activities within a delineated range for optimal memory formation. It is a highly plausible extrapolation to consider that the maintenance of optimal ranges in signaling system activities is also a critical factor in the control of mood, and thus that anti-bipolar therapeutics function by stabilizing the magnitudes of fluctuations in signaling processes to prevent extreme swings in either direction.
Further research is necessary to refine this model, to identify functional consequences of signal stabilization, and to define the links between the stabilization of signaling activity and mood. Considering the two signaling systems discussed here, AP-1 and cyclic AMP, identification of the downstream genes affected by these agents which might contribute to therapeutic responses provides one immediate goal. As proposed for antidepressants, 33 studies of growth factors regulated by these signaling systems may be particularly rewarding considering the accumulating evidence of atrophy in specific brain regions associated with depression which may also be involved in bipolar disorder. 34, 35 Although simple in concept, the bimodal model of the mechanism of action of lithium and other antibipolar therapeutics may provide a useful framework for integrating complex biochemical and behavioral responses to therapeutics, for designing experiments to further clarify the actions of these drugs, for assisting interpretation of results which may contribute to modifications of the model, and ultimately in providing clues about the underlying abnormalities contributing to bipolar mood disorder.
